Nuclidium highlights studies at EANM 2023

By staff writers

September 5, 2023 -- Nuclidium noted that studies highlighting its programs will be presented at the upcoming European Association of Nuclear Medicine (EANM) 2023 meeting.

The meeting is being held in Vienna from 9-13 September and will include presentations of positive preclinical and clinical translational data for diagnostic candidates from three of Nuclidium's precision oncology programs; namely, its copper-based theranostic CuTrace programs targeting epithelial tumors (Kalios), neuroendocrine tumors (TraceNET), and prostate cancer (NuriPro).

The data, presented in two oral presentations and a poster presentation, support the advancement of these three programs into clinical translation, the company said.

Full details on the presentations can be found here.

Copyright © 2023

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking